Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Quinnova Pharmaceuticals (Newtown, PA) a commercial-stage specialty biopharma company focused on dermatological drug reformulations and foam delivery systems, closed a $17.4M Series B financing. Participants include Safeguard Scientifics, Thomas, McNerney & Partners, H.I.G. Ventures.

ProCertus BioPharm (Madison, WI) a clinical-stage developer of treatments to combat the side effects of chemotherapy and radiotherapy, e.g. alopecia, dermatitis and oral mucositis, closed a $2.1M Series A. Participants include Novartis Venture Fund and Venture Investors.

Kythera Biopharmaceuticals (Calabasas, CA) a clinical-stage biopharmaceutical company focused on aesthetic dermatology, closed a $10M Sereis C financing, bringing the total round to $40M. Participants include Versant Ventures, ARCH Venture Partners, Prospect Venture Partners, BBT Capital Management, JAFCO Ventures and Altitude Life Science Ventures.

Garnet Biotherapeutics (Malvern, PA) a regenerative medicine company focused on dermatology, closed a $10.4M Series A financing. Participants include SCP Vitalife Partners, Safeguard Scientifics and Alliance Technology Ventures.

Sol-Gel Technologies (Israel) developer of microencapsulation technology topical products for the dermatology applications, closed a $9M Series B financing. Participants include Medica Venture Partners, JVP and DSM Corporate Venturing.

Serentis (United Kingdom) early-stage dermatology company, closed a $8.2M Series A financing. Participants include MVM Life Science Partners, Apposite Capital, East Hill and Novo.

Collegium Pharmaceutical (Cumberland, RI) commercial-stage specialty pharmaceutical company focused on late-stage development therapeutics for central nervous system, respiratory and skin related disorders, closed a $20M Series D financing. Participants include Frazier Healthcare Ventures.

Creabilis Therapeutics (Italy) dermatological drug start-up focused on psoriasis, dermatitis, and Behcet’s Disease, closed a $25M Series A financing. Participants include Sofinnova Partners and NeoMed Management.

Myoscience (Redwood City, CA) early-stage biotech focused on dermatology and aesthetic medicine closed a $8.4M Series B financing. Participants include Accuitive Medical Ventures, De Novo Ventures and Saratoga Ventures.

Quinnova Pharmaceuticals, Inc., a specialty dermatological reformulation pharmaceutical company focused on innovative dermal drug delivery platforms, has completed a $13.6M Series A round of financing. Participating in the round are Thomas, McNerney & Partners, H.I.G. Ventures and an investor syndicate led by Omnivest (Bermuda) Ltd.

« Previous Page  Next Entries »

to top of page...